Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Yoseph Caraco"'
Autor:
Clara Weil, Tobias Bergroth, Anna Eisenberg, Yohance Omar Whiteside, Yoseph Caraco, Lilac Tene, Gabriel Chodick
Publikováno v:
Epidemiologia, Vol 4, Iss 3, Pp 309-321 (2023)
Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2 Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This retrospective cohort study aimed to describe characteristics of patients offered C
Externí odkaz:
https://doaj.org/article/5cbdbe7d0a6e4f1099bd101704da915f
Autor:
Ayala Kobo-Greenhut, Adit Zohar-Beja, Liron Hadar, Lior Itzhaki, Avraham Karasik, Yoseph Caraco, Hilel Frankenthal, Daniel Shahaf, Dana Ekstein, Iris Shichor, Eitan Gur
Publikováno v:
Journal of Eating Disorders, Vol 11, Iss 1, Pp 1-15 (2023)
Abstract Background Binge-eating disorder) BED) is the most common eating disorder in the United-States. Daily, orally administered topiramate has shown BED treatment efficacy, with two major limitations: frequent and severe side effects and slow tim
Externí odkaz:
https://doaj.org/article/ba95ad9a540b4cdbb82a84c83f211d6e
Autor:
Marc Gotkine, Yoseph Caraco, Yossef Lerner, Simcha Blotnick, Maor Wanounou, Shalom Guy Slutsky, Judith Chebath, Graciela Kuperstein, Elena Estrin, Tamir Ben-Hur, Arik Hasson, Kfir Molakandov, Tehila Sonnenfeld, Yafit Stark, Ariel Revel, Michel Revel, Michal Izrael
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Malfunction of astrocytes is implicated as one of the pathological factors of ALS. Thus, intrathecal injection of healthy astrocytes in ALS can potentially compensate for the diseased astrocytes. AstroRx® is an allogeneic cell-ba
Externí odkaz:
https://doaj.org/article/3ddbc58896384d3a9d1071138a07d1a3
Autor:
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic as
Externí odkaz:
https://doaj.org/article/1ec46728fbc04f62a659f561489d4b07
Autor:
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations
Externí odkaz:
https://doaj.org/article/2e0b3f45482d4711ba22562ad5a6604c
Autor:
Yfat Yahalom-Ronen, Noam Erez, Morly Fisher, Hadas Tamir, Boaz Politi, Hagit Achdout, Sharon Melamed, Itai Glinert, Shay Weiss, Inbar Cohen-Gihon, Ofir Israeli, Marina Izak, Michal Mandelboim, Yoseph Caraco, Noa Madar-Balakirski, Adva Mechaly, Eilat Shinar, Ran Zichel, Daniel Cohen, Adi Beth-Din, Anat Zvi, Hadar Marcus, Tomer Israely, Nir Paran
Publikováno v:
Vaccines, Vol 10, Iss 2, p 291 (2022)
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specifi
Externí odkaz:
https://doaj.org/article/79c4459068c048c982dd0dd04b24ee33
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The pharmacokinetics of CYP2C9 substrates is characterized by substantial interethnic variability. The objective of the study was to compare CYP2C9 activity by using Phenytoin Metabolic Ratio (PMR) between Ethiopian and non-Ethiopian Jews. PMR was de
Externí odkaz:
https://doaj.org/article/284878a50d6347cd98961944e41a45af
Publikováno v:
Clinical Pharmacokinetics. 61:1187-1198
CYP2C9 is a member of the cytochrome P450 (CYP) superfamily responsible for the metabolism of 16% of drugs that undergo oxidative metabolism. The activity of CYP2C9 exhibits marked inter-individual variability, which translates into prominent differe
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:156-163
Cytochrome P450 2C9 (CYP2C9) is responsible for the oxidative metabolism of about 15% of commonly used drugs, some of which are characterized by a narrow therapeutic window. CYP2C9 is highly polymorphic, and over 60 alleles have been described. CYP2C
Autor:
Amnon Peled, Reuven Or, Yoseph Caraco, Eithan Galun, Arnon Aharon, Abi Vainstein, Rottem Golan, Arnon Nagler, Katia Beider, Orly Eizenberg, Hana Wald, Inbal Mishalian, Shiri Klein, Baruch Bulvik, Yaron Pereg, Michal Abraham
Purpose: The potential of the high-affinity CXCR4 antagonist BL-8040 as a monotherapy-mobilizing agent and its derived graft composition and quality were evaluated in a phase I clinical study in healthy volunteers (NCT02073019).Experimental Design: T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ad058d334dcb420ac9415da299cb8b
https://doi.org/10.1158/1078-0432.c.6525156.v1
https://doi.org/10.1158/1078-0432.c.6525156.v1